Enanta Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
Reports the fiscal third quarter and first nine months ended June 30, 2013; the comparable periods ended June 30, 2012. Enanta is a research-focused biotechnology company with no approved products or product-sale revenue. Its programs include HCV inhibitors and Bicyclolide antibiotics. ABT-450 is being developed by AbbVie in Phase 2 and Phase 3 combination trials; Novartis leads further development of Enanta’s NS5A program, including EDP-239. Enanta funds its independent cyclophilin, nucleotide polymerase, and other early-stage discovery work.
Financial performance and position
Unless otherwise stated, amounts are in millions of dollars. The filing presents no meaningful product gross margin; revenue comes from collaborations and a government research contract.
- Revenue: Q3 was $1.65, down from $2.54 a year earlier. First-nine-month revenue was $30.70, down from $39.85. Q3 revenue comprised $1.18 from NIAID and $0.47 from Novartis research services. Nine-month revenue included AbbVie’s $15.0 Phase 3 milestone, Novartis’ $11.0 Phase 1 milestone, $1.35 of Novartis license/research revenue, and $3.35 from NIAID.
- Profit/loss: Q3 net loss was $4.14, versus a $3.50 loss; loss attributable to common stockholders was also $4.14, or $0.23 per share. Nine-month net income was $14.07, versus $25.45; however, after preferred-stock accretion and allocation to participating securities, common-stockholders’ result was a $2.13 loss, or $0.30 per share. The nine-month income figures were substantially affected by milestone revenue.
- Expenses: Q3 R&D was $4.04 versus $4.93; G&A was $1.79 versus $1.15. Nine-month R&D was $12.54 versus $10.86, reflecting higher early-stage discovery spending, partly offset by lower NS5A and antibiotic costs. Nine-month G&A was $4.43 versus $3.60, mainly due to stock compensation and public-company costs.
- Cash flow: Operating activities provided $13.16 in the first nine months, versus $24.33. Investing used $61.58, mainly as IPO proceeds were invested in marketable securities; financing provided $56.79, principally from the IPO.
- Liquidity and debt: At June 30, cash, cash equivalents, and marketable securities totaled approximately $114.8, versus approximately $45.4 at September 30, 2012. Total assets were $119.67 and total liabilities $5.26; the company reported no debt. Management believed available resources would fund anticipated requirements for at least 24 months.
- Margins: Operating loss was $4.18 in Q3; nine-month operating income was $13.73. The filing provides no product gross-margin measure.
Material changes versus comparable periods
- Nine-month revenue declined primarily because the prior-year period included Novartis’ $34.4 upfront payment; 2013 revenue instead included $15.0 from AbbVie and $11.0 from Novartis milestone payments. Q3 revenue fell as NIAID contract revenue declined.
- The March 2013 IPO raised approximately $59.9 net of underwriting discounts and commissions. Preferred shares converted into common stock at closing; common shares outstanding increased substantially. The company completed a 1-for-4.31 reverse split before the IPO.
- Marketable securities increased materially as IPO proceeds were invested. Accumulated deficit was $103.0 at June 30, 2013.
Outlook, commentary, risks, and unusual items
- Management forecast approximately $17.0 of R&D expense for fiscal 2013, excluding collaborators’ development costs, and expected R&D and public-company G&A costs to increase. Management cautioned that future milestone timing and profitability were uncertain; no approved products or royalties existed.
- Liquidity runway of at least 24 months is management’s estimate and depends on development spending, collaboration payments, and other factors. AbbVie and Novartis control development of their partnered programs and may terminate their agreements; future milestones and royalties are uncertain.
- NIAID’s initial contract term runs through March 2014; additional funding depends on options exercised at NIAID’s discretion. NIAID had notified Enanta of possible effects from federal sequestration, including not exercising options or negotiating reduced terms.
- Clinical, regulatory, competitive, intellectual-property, manufacturing, and financing risks are substantial. The filing notes no threatened or pending litigation, but describes potential third-party IP claims and indemnification exposure. A license amendment creates potential milestones up to $5.0 per qualifying HCV product, plus low-single-digit royalties; a $0.5 milestone payment was made in Q3.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. The filing identifies no off-balance-sheet financing arrangements.
Most important facts for investors to verify
- Progress, trial results, regulatory timelines, and resource commitments for AbbVie’s ABT-450/ABT-493 and Novartis’ EDP-239 programs.
- Whether NIAID exercises future funding options and how any funding changes affect the antibiotic program.
- Cash and investment levels, operating burn, and the assumptions underlying management’s 24-month runway estimate.
- Timing and conditions for collaboration milestones, future royalties, and the $5.0-per-product HCV license obligations.
- R&D spending against the fiscal 2013 estimate and the effects of IPO-related costs, stock compensation, and share dilution.